secwatch / observer
8-K filed January 14, 2025, 6:59 PM ET ticker RAPH CIK 0001415397
leadership confidence high sentiment neutral materiality 0.40

Raphael Pharmaceuticals appoints Ajay Kumar Dhadha as Director and Chairman, replacing Shlomo Pilo

Raphael Pharmaceutical Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ajay Kumar Dhadha

Director and Chairman
RAPH · Raphael Pharmaceutical Inc.
Effective
2025-01-08
Filed
January 14, 2025, 6:59 PM ET
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
Role change

Shlomo Pilo

Chairman
RAPH · Raphael Pharmaceutical Inc.
Effective
2025-01-08
Successor
Ajay Kumar Dhadha
Filed
January 14, 2025, 6:59 PM ET
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ajay Kumar Dhadha was appointed as Director and Chairman at Raphael Pharmaceutical Inc..

Action
appointed
Role
Director and Chairman
Exact text from the filing
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Shlomo Pilo changed role as Chairman at Raphael Pharmaceutical Inc..

Action
replaced
Role
Chairman
Exact text from the filing
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
View on SEC.gov

Raphael Pharmaceutical Inc. filing history →

Source: SEC EDGAR
accession 0001213900-25-003401
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.